凤麟 吴

Mr. 凤麟 吴


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in Gene
Verified
Journal Article
Closed access
JHJiayi Han
Jiayi Han
JHJianqing Huang
Jianqing Huang
JHJieming Hu
Jieming Hu
WSWenkai Shi
Wenkai Shi
HWHongqiong Wang
Hongqiong Wang
凤吴凤麟 吴
凤麟 吴

10 January 2022 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
LYLijun Yan
Lijun Yan
YOYusheng Ou
Yusheng Ou
SXShengfang Xia
Shengfang Xia
JHJianqing Huang
Jianqing Huang
WZWenfeng Zhang
Wenfeng Zhang
凤吴凤麟 吴
凤麟 吴

19 April 2025 in Genes
Verified
Journal Article
Open access
PDF file
SWShi Wenkai
Shi Wenkai
JHJieming Hu
Jieming Hu
FWFenglin Wu
Fenglin Wu
钟钟钟慧珊 钟
钟慧珊 钟
WZWenfeng Zhang
Wenfeng Zhang
凤吴凤麟 吴
凤麟 吴
Background: Adoptive cell therapy (ACT), including CAR-T and TCR-T therapies, shows promise for cancer treatment, depending on infused T cell expansion, persistence and activity. We previously characterized four T-cell subsets (TN, TSCM, TCM and TEM) and their miRNA profiles. Objectives: This study investigates miR-143-3p’s role in T cell differentiation. Methods: Using qPCR, we analyzed miR-143-3p expression. Target genes were validated by dual-luciferase assays. Functional assays assessed differentiation markers, proliferation, apoptosis and cytokine secretion. Results: miR-143-3p was upregulated in early-differentiated TSCM but downregulated during progression. We confirmed ABL2 and PAG1 as direct targets suppressed by miR-143-3p. Overexpression increased early markers (LEF1, CCR7 and CD62L) while decreasing late markers (EOMES, KLRG1 and CD45RO). It also enhanced proliferation, reduced apoptosis and suppressed cytokine secretion. Conclusions: miR-143-3p promotes TSCM differentiation and inhibits progressive differentiation by targeting ABL2/PAG1, suggesting new ACT optimization strategies.